Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease
Go back to Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease| (NASDAQ: SAVA) | Delayed: 21.73 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.73 | 52 Week High | $ | |||
| Open | $21.73 | 52 Week Low | $ | |||
| Day High | $21.73 | P/E | N/A | |||
| Day Low | $21.73 | EPS | $ | |||
| Volume | 1,232 | |||||
